Edition:
United Kingdom

Ucb SA (UCB.BR)

UCB.BR on Brussels Stock Exchange

75.84EUR
18 Jan 2019
Change (% chg)

€-1.56 (-2.02%)
Prev Close
€77.40
Open
€77.62
Day's High
€77.78
Day's Low
€75.78
Volume
344,757
Avg. Vol
374,268
52-wk High
€81.48
52-wk Low
€60.08

Chart for

About

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia,... (more)

Overall

Beta: 0.92
Market Cap(Mil.): €11,689.79
Shares Outstanding(Mil.): 194.51
Dividend: 1.15
Yield (%): 1.34

Financials

  UCB.BR Industry Sector
P/E (TTM): 17.05 30.48 33.71
EPS (TTM): 3.53 -- --
ROI: 8.89 14.98 14.48
ROE: 12.31 16.31 15.99

Drugmaker UCB backs Brexit Britain with 1 billion pound investment

LONDON Belgian drugmaker UCB expects to invest about 1 billion pounds in Britain over the next five years, throwing its support behind the country's life sciences sector despite Brexit uncertainty.

05 Dec 2018

CORRECTED-BRIEF-UCB's Midazolam Nasal Spray Granted Orphan Drug Designation

* FDA ACCEPTS NEW DRUG APPLICATION (NDA) TO REVIEW MIDAZOLAM NASAL SPRAY

13 Aug 2018

Earnings vs. Estimates